AP also noted: "We are confident that all of these patents will emerge from this process substantively unchanged," Martin McGlynn, president and chief executive officer of StemCells, said in a statement. "We firmly believe that in time Neuralstem will be found by the courts to be infringing our patents."
IPBiz notes that the precipitating event apparently was a decision by the USPTO granting a re-exam request of claims of the StemCells patents. News-medical net reported:
The U.S. Patent Office recently ruled in favor of Neuralstem and ordered re-examinations of all the StemCells Inc. patents in a suit finding that there were "serious new questions of patentability" problems with each claim of every patent under re- examination.
IPBiz reminds people that the Eolas patent, questioned by many, survived re-exam without changes to the claims. Patents of Thomson / WARF are currently in re-exam.